Predicting CD4 count using total lymphocyte count: A sustainable tool for clinical decisions during HAART use

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 1, 2005, Pages 58-62

  Mwamburi, D Mkaya ^a   Ghosh, Mayurika ^a   Fauntleroy, Jim ^b   Gorbach, Sherwood L ^b   Wanke, Christine A ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HEMOGLOBIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; GENDER; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE REGRESSION; PATIENT MONITORING; PREDICTION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

EID: 24644441215     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.58     Document Type: Article

References (20)

1. Crowe S, Turnbull S, Oelrichs R, Dunne A, 2003. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 37 (Suppl 1): S25-S35.
2. Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, Thyagarajan S, Solomon S, 2002. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J AIDS 31: 378-383.
3. Spacek LA, Griswold M, Quinn TC, Moore RD, 2003. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 17: 1311-1317.
4. van der Ryst E, Kotze M, Joubert G, Steyn M, Pieters H, van der Westhuizan M, van Staden M, Venter C, 1998. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. J AIDS Human Retrovirol 19: 238-244.
5. WHO, 2004. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003 revision). Available at http://www.who.int/3by5/publications/en/arv_eng.pdf.
6. Schreibman T, Friedland G, 2004. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis 32: 257-262.
7. Le Moing V, Chene G, Carrieri MP, Besnier JM, Masquelier B, Salamon R, Bazin C, Moatti JP, Raffi F, Leport C, APROCO Study Group, 2001. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J AIDS 27: 372-376.
8. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL, 2000. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31: 803-805.
9. Tang AM, Forrester J, Spiegelman D, Knox TA, Tachetgen E, Gorbach SL, 2002. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J AIDS 31: 230-236.
10. Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernandez-DiFranco MG, Knox TA, 1998. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12: 1645-1651.
11. Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL, 2000. Relation of lean body mass to health-related quality of life in persons with HIV. J AIDS 24: 137-146.
12. Woods MN, Tang AM, Forrester J, Jones C, Hendricks K, Ding B, 2003. Effect of dietary intake and protease inhibitors on serum vitamin B12 levels in a cohort of human immunodeficiency virus-positive patients. Clin Infect Dis 37 (Suppl 2): S124-S131.
13. Wanke CA, Silva M, Ganda A, Fauntleroy J, Spiegelman D, Knox TA, Gorbach SL, 2003. Role of acquired immune deficiency syndrome-defining conditions in human immunodeficiency virus-associated wasting. Clin Infect Dis 37 (Suppl 2): S81-S84.
14. Knox TA, Spiegelman D, Skinner SC, Gorbach S, 2000. Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. Am J Gastroenterol 95: 3482-3489.
15. Forrester JE, Woods MN, Knox TA, Spiegelman D, Skinner SC, Gorbach SL, 2000. Body composition and dietary intake in relation to drug abuse in a cohort of HIV-positive persons. J AIDS 25 (Suppl 1): S43-S48.
16. Beck EJ, Kupek EJ, Gompels MM, Pinching AJ, 1996. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS 7: 422-428.
17. Badri M, Wood R, 2003. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 17: 541-545.
18. Flanigan TP, M.A., Kumarasamy N, et al. 2002. Total lymphocyte count (TLC) as a surrogate for CD4 count to initiate and monitor HAART in resource-limited countries [abstract 456-W]. In 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Seattle: Foundation for Retrovirology and Human Health.
19. Selker HP, 2001. Cardiac time-insensitive predictive instruments (TIPIs): real-time emergency clinical decision aids and tools for the retrospective assessment of care. Maryland Medicine Suppl: 95-97.
20. Aufderheide TP, Rowlandson I, Lawrence SW, Kuhn EM, Selker HP, 1996. Test of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) for prehospital use. Ann Emerg Med 27: 193-198.